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Abstract
TLRs, including TLR4, play a crucial role in inflammatory-based diseases, and TLR4 has been identified as a therapeutic
target for pharmacological intervention. In previous studies, we investigated the potential of FP7, a novel synthetic
glycolipid active as a TLR4 antagonist, to inhibit haematopoietic and non-haematopoietic MyD88-dependent TLR4 pro-
inflammatory signalling. The main aim of this study was to investigate the action of FP7 and its derivative FP12 on
MyD88-independent TLR4 signalling in THP-1 derived macrophages. Western blotting, Ab array and ELISA approaches
were used to explore the effect of FP7 and FP12 on TRIF-dependent TLR4 functional activity in response to LPS and
other endogenous TLR4 ligands in THP-1 macrophages. A different kinetic in the inhibition of endotoxin-driven TBK1,
IRF3 and STAT1 phosphorylation was observed using different LPS chemotypes. Following activation of TLR4 by LPS,
data revealed that FP7 and FP12 inhibited TBK1, IRF3 and STAT1 phosphorylation which was associated with down-
regulation IFN-b and IP-10. Specific blockage of the IFN type one receptor showed that these novel molecules inhibited
TRIF-dependent TLR4 signalling via IFN-b pathways. These results add novel information on the mechanism of action of
monosaccharide FP derivatives. The inhibition of the TRIF-dependent pathway in human macrophages suggests potential
therapeutic uses for these novel TLR4 antagonists in pharmacological interventions on inflammatory diseases.
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Introduction
The incidence of inflammatory-based diseases has
increased dramatically due to a variety of environmen-
tal factors. Over the last few decades, a solid body of
research papers have identified many therapeutic tar-
gets and anti-inflammatory compounds which have
been validated for treatment of these disorders. Lack
of target specificity and side effects are the current
problems hampering clinical application of small
molecular anti-inflammatory drugs.1–3 Discovery of
novel target-specific compounds for treatment of
these diseases is a big challenge with potentially signif-
icant scientific, commercial and social impacts. TLRs
are PRRs within the immune system, and TLR recog-
nition of microbial PAMP or endogenous DAMP
(danger-associated molecular patterns) leads to the
activation of inflammation and triggering of the
innate immune response.4–5 TLR4 is the main sensor
specific for LPS that represents the main outer mem-
brane component of most Gram-negative bacteria.6
TLR4 activation by endogenous ligands (DAMPs)
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and signalling has been implicated in the pathogenesis
of a number of inflammatory-related diseases.7
Following ligand recognition, TLR4 may activate
MyD88-dependent or TRIF-dependent signalling path-
ways. MyD88-dependent signalling is associated with
downstream activation of NF-kB and production of
pro-inflammatory cytokines and chemokines.9 TRIF-
dependent signalling is typically associated with IRF3
and production of type 1 IFN, as well as late phase
NF-kB activation via TRAF6.9 While TLR3/TRIF-
dependent signalling may have some protective effect
against cardiovascular disease, TLR4/TRIF-dependent
signalling is considered pro-atherogenic.10 Therefore,
TLR4-specific antagonists of TRIF signalling are also
of great interest for treatment of these diseases. The
deletion of the TLR4 gene in haematopoietic and
non-haematopoietic cells protected against a variety
of inflammatory-based diseases.11–13 These findings
strongly support the idea that regulation of TLR4
may be a promising target for therapeutic control of
inflammatory-related disorders.14
Over the last two decades, TLR4 antagonists have
been evaluated in pre-clinical and clinical studies; how-
ever, none have been approved yet for clinical use.
Therefore, the discovery of novel TLR4 modulators is
an important target for the pharmaceutical industry.
Recently, we have developed synthetic glycolipids,
named FP7 and FP12, as TLR4 antagonists.15 FP7
and FP12 compete with LPS (and other ligands) for
the MD-2 binding site, thus inhibiting TLR4 activation
(formation of the TLR4/MD-2/LPS complex).15 In a
previous study we have shown the ability of FP7 to
negatively regulate MyD88-dependent TLR4 signalling
in both non-haematopoietic and haematopoietic cells,
which suggests that this TLR4 antagonist could poten-
tially be used therapeutically for the treatment of
inflammatory-related diseases.16 The main aim of this
study was to further investigate the potential of these
novel molecules to affect MyD88-independent or
TRIF-dependent TLR4 signalling pathways in THP-1
macrophages. Our results identified specific targets for
FP7 and FP12, by which they inhibited LPS-driven




TLR4 antagonists FP7 and FP12 were synthesized in
Prof F Peri laboratories (University of Milano-
Bicocca) by multistep organic synthesis and the purity
and identity of the compounds was confirmed by
NMR, mass spectrometry and HPLC analyses.16 For
TLR4-exclusive and potent activation, LPS
(Salmonella Minnesota (SM) (Re), TLRpureTM), LPS
(SM (Ra), TLRpureTM), LPS (SM (S-form),
TLRpureTM), Lipid A (SM, TLRpureTM) and LPS
from Escherichia coli (Re) were used (Innaxon
Biosciences, Tewkesbury, UK). For in vitro experi-
ments FP7 and FP12 were reconstituted in DMSO/eth-
anol (1:1) (vol: vol). Anti-human IFNR2 neutralizing
Ab (clone MMHAR-20) was purchased from PBL
Assay Science, USA.
Cell maintenance and treatment
THP-1 cells were obtained from the European
Collection of Animal Cell Cultures (Salisbury,
Wiltshire, UK) and cultured in RPMI (þ10% heat
inactivated FBS, (HIFBS)), þ1% glutamine, þ1%
penicillin/streptomycin). Cells were split three times
weekly and maintained at a density of 0.3 106
cells/ml. For differentiation of THP-1 cells, 25 nM of
PMA (phorbol 12-myristate 13-acetate) was added to
plated cells for 3 d before washing three times with
fresh medium. Cells were then left to rest overnight
before treatment. All cells were pre-treated with FP7
and FP12 (10 lM) for 1 h, then exposed to LPS (100
ng/ml) for 0 to 16 h. In some experiments, cells were
simultaneously incubated with FP (Francesco Peri)
compounds and LPS, or FP compounds were added
to culture medium 30 min after LPS.
Western blot analysis of protein expression and
phosphorylation
Cell lysates (50 lg) were separated on 7.5% TGX gels,
transferred onto polyvinyldifluoride membranes
(Bio-Rad, UK) and blocked using 5% (wt/vol)
skimmed milk in tris-buffered saline (TBS)/0.1% (vol/
vol) tween-20 for 1 h at room temperature. Blots were
incubated overnight at 4C with primary Abs:
phospho-p38 (4511), phospho-p65 NF-kB (3031),
b-actin (12262), phospho-TBK1 (5483), phospho-
IRF3 (4947) or phospho-STAT1 (9167) from Cell
Signalling Technology (NEB, Herts, UK) (1:1000 dilu-
tion in TBS, 1% milk). After washing in TBS/0.1%
(vol/vol) tween-20, blots were incubated with HRP-
conjugated secondary Ab at room temperature for 1
h in TBS/0.1% (vol/vol) tween-20 and 5% milk.
After the final wash, immunoreactivity was visualized
using the chemiluminescent substrate ECL Plus (Bio-
Rad, UK). G-Box imaging system and Genesys soft-
ware (Synoptics UK) were used to visualize blots and
densitometry analysis was performed using Genetools
(Synoptics UK). The level of cellular beta actin was
used as a loading control.
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Inflammation Ab array
THP-1 macrophages were treated with FP7 or FP12
(10 mM) for 1 h prior to LPS (100 ng/ml) exposure.
Culture medium was collected after 18 h of incubation
and analysed on a human inflammation array (Ray-
Biotech, USA) containing 40 pro-inflammatory pro-
teins to assess relative levels of cytokine expression by
samples.16 Results values are expressed as fold-increase
relative to control samples.
ELISA
Human IFN-b and IP-10 production were measured in
cell culture medium (10–100 ll) using ELISA kits
(R&D Systems, USA and Ray-Biotech, USA) follow-
ing the manufacturer’s instructions. At the final stage,
absorbance was measured at 450 nm using the Sunrise
(Tecan Group LTD., Switzerland) microplate reader.
Protein concentration was calculated using GraphPad
Prism version 7.01.
Statistical analysis
Results were analysed by one-way ANOVA followed
by the post-hoc test (Tukey) for multiple comparisons
using GraphPad Prism version 7.01. A value of
P< 0.05 was considered significant.
Results
Time-dependent activation of TBK1 and STAT1 in
TRIF-dependent TLR4 signalling in response to a
selection of TLR4-selective agonists in THP-1
macrophages
TLR4 signalling has been shown to play a critical role
in the functional activity of immune-competent cells at
any stage of the inflammatory process. It has been
shown that a prolonged activation of the receptor as
a result of stimulation by PAMPs and DAMPs can
lead to chronic microbial or sterile inflammations asso-
ciated with the development and progression of inflam-
matory diseases. To study the effect of FP7 and FP12
on MyD88-independent TLR4 signalling, THP-1-
derived human macrophages were used as an in vitro
cell model. The experimental design was based on two
readouts: the activation of TLR4 second messengers
and the production of TLR4-dependent pro-inflamma-
tory proteins associated with this pathway.
To identify a suitable inducer of TRIF-dependent
TLR4 signalling, initially we tested the ability of
known TLR4 agonists to induce TBK1 and STAT1
phosphorylation.
Deep rough LPS (Re-LPS) from SM, known to
potently activate MyD88-dependent TLR4 signalling,
did not activate second messengers involved in TRIF-
dependent TLR4 signalling (Supplemental Figure 2).
Different types of LPS can excite differential effects
on TLR4 signalling pathways, and two other forms
of SM LPS (S, smooth/wild type and Ra, rough
form), as well as with lipid A, were tested. While S-
LPS and Ra-LPS produced a significant increase in
the levels of TBK1 (Figure 1a) and STAT1 phosphor-
ylation (Figure 1b) compared with the control, no sig-
nificant effect was seen in response to Re-LPS or lipid
A. S-form LPS (SM) was therefore selected for all sub-
sequent experiments on TRIF-dependent TLR4
signalling.
To select the appropriate timing for measurement of
phosphorylation events, THP-1 macrophages were
exposed to LPS (S-form, SM), and cell lysates were
collected over a period of 6 h. Following exposure to
LPS (S-form, SM), levels of both TBK1 (Figure 1c) and
STAT1 phosphorylation (Figure 1d) were increased.
TBK1 phosphorylation was detected at 30 min follow-
ing LPS treatment, whereas phospho-STAT1 remained
below a significant threshold until 2.5–3 h. From this,
30 min and 2.5–3 h were selected for further experi-
ments for measuring TBK1 and STAT1 phosphoryla-
tion, respectively. Similarly, we found that
phosphorylation of IRF3 (downstream target for
TBK1) was elevated between 45–60 min following
exposure to LPS (data is not shown). In summary,
these results demonstrated substantial differences in
the times taken for MyD88 and TRIF-dependent
TLR4 signalling.
FP7 and FP12 suppress LPS-induced TBK1 and
IRF3 phosphorylation in THP-1 macrophages
We have previously shown that FP7 can reduce
MyD88-dependent TLR4 signalling at the second mes-
sengers (p65 NF-kB and p38 MAPK) level in THP-1
macrophages.14 Similarly to FP7, we found that FP12
can also negatively regulate MyD88-dependent TLR4
signalling at IL-1b level in response to S- and Re-forms
of SM LPS (Supplemental Figure 3). However, we
wanted to determine the effects of FP7 and FP12 on
the alternative TRIF-dependent TLR4 signalling path-
way. For this purpose, we analysed their effect on acti-
vation of TBK1 and IRF3 as second messengers in this
pathway. Following up-regulation of targeted second
messengers in response to LPS (S-form, SM), both FP7
and FP12 significantly reduced TBK1 (Figure 2a) and
IRF3 (Figure 2b) phosphorylation, to a level compara-
ble with the controls. These results suggested that FP7
and F12 can negatively regulate TRIF-dependent
TLR4 signalling at a level of second messengers in
THP-1 macrophages.
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Figure 1. Effect of different TLR4 ligands on TBK1 and STAT1 phosphorylation. (a-b) THP-1-derived macrophages we exposed to
LPS (S, Re, Ra), and lipid A (all from SM) and TBK1 and STAT1 phosphorylation was measured by Western blotting at 0.5 and 2.5 h,
respectively. (c-d) THP-1-derived macrophages were exposed to LPS (SM, S-form) for 0.5-6 h and TBK1 and STAT1 phosphorylation
was measured via Western blotting. Actin was used as a loading control. Results are shown as mean SD of three independent
experiments. Significant results are indicated as *P< 0.05 and **P< 0.01 versus control.
Figure 2. FP7 and FP12 negatively regulate TRIF-dependent TBK1 and IRF3 phosphorylation. THP-1-derived macrophages were
pre-treated with FP7 (10 mM) or FP12 (10 mM) for 1 h before exposure to LPS (S-form) (100 ng/ml). Cell lysates were prepared after
0.5 h and TBK1 and IRF3 phosphorylation was measured via Western blotting. Actin was used as a loading control. Results are shown
as mean SD of three independent experiments. Significant results are indicated as ***P< 0.001 versus control.
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Time-dependent production of IFN-b and IP-10 in
TLR4 signalling in response to selective TLR4
agonists in THP-1 macrophages
We explored whether FP7 and FP12 could have an
impact on LPS-driven production of pro-
inflammatory proteins in TRIF-dependent TLR4 sig-
nalling in THP-1 macrophages. Initially, we used
human inflammation Ab array (containing 40 pro-
inflammatory proteins) to screen specific target
molecules of interest. The semi-quantitative analysis
demonstrated that FP7 and FP12 inhibited, to various
extents, the expression of 17/20 LPS(SM)-driven pro-
inflammatory proteins including IP-10, which is an
IFN-dependent protein the production of which is
associated with TLR4/TRIF signalling (Supplemental
Table 1). Previously, we have validated the blocking
effect of FP7 on the production of TLR4/MyD88-
dependent proteins such as IL-1b, IL-6, IL-8, TNFa,
MCP-1, MIP-1, etc.16 In this study, we investigated the
modulating effect of these novel molecules on the pro-
duction of IFN-related proteins (IFN-b and IP-10). We
did not include IFN-c in the list because LPS did not
appear to affect the release of this protein from human
macrophages at 24 h.
Furthermore, we applied the same experimental
approach as with second messengers. To determine
which LPS form was most appropriate for analysing
IFN-b and IP-10 production, we used three forms of
LPS (S, Re and Ra), as well as lipid A. While S and Ra
forms produced a significant increase in production of
IP-10 (Figure 3a) and IFN-b (Figure 3b) compared
with the control, no significant effect was seen in
response to Re-LPS or lipid A.
Hence, the S-form of LPS was selected for all sub-
sequent end point experiments involving TRIF-
dependent TLR4 signalling. Additionally, we moni-
tored the time course of IFN-b and IP-10 production.
Interestingly, only LPS (S-form) produced a significant
increase in IFN-b and IP-10. Following LPS stimula-
tion, we found major differences in the time courses of
the release of these IFN proteins. IP-10 was released
within 6 h of LPS exposure and the level was further
increased at 24 h (Figure 3a). In contrast, the initial
increase in IFN-b production at 2–6 h was followed
by a drop in IFN-b level by 24 h (Figure 3b). This
data demonstrates that a short time of IFN-b availabil-
ity might be associated with the signalling properties of
this molecule through IFN receptor alpha/beta
(IFNAR). Following this, experiments involving IP-
10 and IFN-b were considered after 24 and 2.5 h of
LPS exposure, respectively.
FP7 and FP12 negatively regulate LPS-induced IFN-b
and IP-10 production in THP-1 macrophages
In the next series of experiments, we validated the
TLR4-modulating effect of FP7 and FP12 on IFN-b
and IP-10 production. THP-1 macrophages were pre-
treated with FP7 or FP12 prior to LPS exposure to
determine the effect of these molecules on TLR4/
TRIF-dependent pro-inflammatory protein produc-
tion. IFN-b and IP-10 were measured in culture
medium after 2.5 and 24 h, respectively. Both FP7
and FP12 significantly down-regulated IFN-b and IP-
10 production following LPS (S chemotype) stimula-
tion (Figure 4).
Recently, we have provided evidence demonstrating
that, irrespective of the method of administration
Figure 3. Time-dependent production of IFN-b and IP-10 in TLR4 signalling in response to different chemotypes of LPS as TLR4
selective agonists in THP-1 macrophages. THP-1 macrophages were treated with LPS (100 ng/ml) and lipid A (100 ng/ml) and medium
collected at 2, 6 and 24 h. IP-10 (a) and IFN-b (b) release were measured via ELISA. Results are shown as mean SD of three
independent experiments. Significant results are indicated as *P< 0.05 or ***P< 0.001 versus control.
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(prior, simultaneously and even post LPS exposure),
FP7 down-regulated MyD88-dependent cytokines pro-
duction in THP-1 macrophages.16 Following the same
experimental approach, the results showed the ability
of FP7 to reduce TLR4-dependent IFN-b (Figure 4a)
or IP-10 (Figure 4b) irrespective of time of the admin-
istration of LPS. While FP12 significantly reduced
IFN-b production in prior and simultaneous treat-
ments, post LPS treatment with FP12 did not affect
IFN-b production (Figure 4a). Similar to FP7, FP12
negatively regulated IP-10 production (Figure 4b). This
data suggested that FP7 and FP12 are negative modu-
lators of type I IFN production, however FP12 was
found less effective on TRIF-dependent TLR4 signal-
ling post factum.
FP7 and FP12 block LPS-induced STAT1
phosphorylation via IFN-b signalling in THP-1
macrophages
To further investigate the mechanism by which novel
TLR4 antagonists block TLR4/TRIF signalling in
macrophages we carried out mechanistic experiments
using a specific blocking Ab to prevent IFNAR acti-
vation in response to IFN-b. As a readout, we used
phosphorylation of STAT1, a well-known second mes-
senger in IFN signalling. Following LPS exposure or
direct exogenous IFN-b stimulation, a significant
increase in STAT1 phosphorylation was observed
(Figure 5a and 5b).
LPS or IFN-b-induced STAT1 phosphorylation was
countered by blocking IFNAR in either case, suggest-
ing that IFNAR activation was required for LPS/
TLR4-induced STAT1 activation in THP-1 macro-
phages. Furthermore, the results demonstrated that
both FP7 and FP12 significantly reduced
TLR4-dependent STAT1 phosphorylation, but they
did not affect exogenous IFN-b-induced STAT1 phos-
phorylation in THP-1 macrophages.
We obtained similar data using IP-10 production as
a readout in THP-1 macrophages. The specific block-
age of IFNAR prevented LPS from elevating IP-10
production (Figure 5d). FP7 and FP12 significantly
reduced IP-10 production but they did not have any
impact on exogenous IFN-b-induced IP-10 release
from THP-1 macrophages (Figure 5c). These results
suggest that FP7 and FP12 can block LPS-induced
STAT1 activation via inhibition of IFN-b production
in THP-1 macrophages.
Discussion
Chronic inflammation has been documented as a crit-
ical event in a variety of inflammatory-related diseases.
In this context, we have shown the essential role of
TLR4 as a therapeutic target and suggest that the mod-
ulation of TLR4 signalling pathways will be beneficial
for treatment.17,18 Pharmacological intervention of a
variety of diseases using TLR4 antagonists has been a
challenging approach for the last few decades. For
example, Eritoran has previously been shown to pre-
vent TLR4/TRIF-dependent signalling.19 However,
these candidates failed in different stages of clinical
trials.20,21 Therefore, the generation of novel TLR4
modulators, which are in different stages of pre-
clinical or clinical validation, will be beneficial for the
treatment in a broad range of inflammatory-related
diseases including cancer.22
After a first generation of synthetic cationic amphi-
philes (IAXO compounds) active in inhibiting TLR4
Figure 4. Effect of FP7 and FP12 on IFN-b and IP-10 production in prior, simultaneous and post LPS exposure. THP-1-derived
macrophages were pre-treated with FP7 or FP12 30 min before, at the same time, and 30 min after LPS (S-form, 100 ng/ml) exposure.
Medium was collected at 2.5 h for IFN-b and 24 h for IP-10. IFN-b (a) and IP-10 (b) release was measured via ELISA. Results are shown
as mean SD of three independent experiments. Significant results are indicated as *P< 0.05, **P< 0.01 or ***P< 0.001 versus
control.
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signal, our group developed a second generation of
anionic, glycolipid-based TLR4 antagonists designated
as FP molecules. As a result of the screening, we iden-
tified FP7 and FP12 as potent inhibitors of TLR4
which bind to MD-2 and displace LPS from TLR4
complex.15 Consequently, we investigated the molecu-
lar mechanisms by which these molecules affect TLR4
signalling in the context of inflammatory diseases.
Previously, we documented that the novel synthetic
TLR4 antagonist FP7 inhibited TLR4 function and
glycolytic re-programming of dendritic cells, and pro-
tected mice from death due to TLR4-dependent influ-
enza infection.23 Interestingly, we showed that FP7
completely blocked the production of HMGB-1 (high
mobility G box 1 protein, necrotic release factor)-
induced TLR4-dependent pro-inflammatory cytokines
from dendritic cells. These findings demonstrated that
the negative regulation of TLR4 signalling by novel
specific antagonists in response to DAMP-driven
amplification of the immune response could be benefi-
cial for virus-associated infectious diseases.
Moreover, we demonstrated that FP7 efficiently
protected motor-neurons from LPS-induced lethality
in spinal cord cultures, and inhibited IL-1b production
from LPS-stimulated microglia in an amyotrophic lat-
eral sclerosis mouse model.24 In another study, we
showed that FP7 had the potential to inhibit haemato-
poietic and non-haematopoietic MyD88-dependent
TLR4 signalling in response to distinct TLR4 ligands
of sterile and non-sterile inflammation.16 Very recently,
we reported the anti-inflammatory role of FP7 in
inflammatory bowel disease (IBD).25 FP7 strongly
reduced LPS-driven release of pro-inflammatory pro-
teins in PBMCs isolated from IBD patients and lamina
propriamononuclear cells isolated by biopsy of patients
with Crohn’s disease and ulcerative colitis.
Additionally, FP7 attenuated colonic inflammation in
a mouse model of ulcerative colitis.25
Figure 5. FP7 and FP12 block LPS-induced STAT1 phosphorylation via IFN-b signalling in THP-1-derived macrophages. THP-1
macrophages were pre-treated with FP7, FP12 (10 lM) and IFNAR neutralizing Ab (1 lg/ml) 1 h prior to LPS (S-form) exposure. Cell
lysates and medium were collected after 2.5 and 24 h, respectively. STAT1 phosphorylation (a, b) and IP-10 production (c, d) were
measured via Western blotting and ELISA, respectively. Results are shown as mean SD of three independent experiments. Significant
results are indicated as *P< 0.05, **P< 0.01 or ***P< 0.001 versus control.
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In this study we further demonstrated the potential
of the TLR4 antagonist FP7 and its novel derivative
FP12 to block MyD88-independent TLR4 signalling in
human macrophages. We showed the ability of FP7
and FP12 to negatively regulate the activity of second
messengers (TBK1, IRF3 and STAT1) and IFN pro-
teins production (IFN-b and IP-10) implicated in
TRIF-dependent TLR4 signalling. Interestingly, we
found differential properties of different structural var-
iants of LPS to activate TRIF-dependent TLR4 path-
ways. While LPS forms purified from SM wild type or
mutant strains and SM derived lipid A all activated
MyD88-dependent TLR4 pathways, only S and Ra
forms of LPS were linked with the activation of
TRIF-dependent pathways in THP-1 macrophages.
Additionally, we observed that the same properties of
LPS forms are valid for activation of MyD88-
dependent pathways based on p65 NF-kB phosphory-
lation (data is not shown). In support, meningococcal
lipid A was shown as a weak agonist in stimulating
TLR4/TRIF signalling in human macrophages,26 In
contrast, monophosphoryl lipid A has been shown to
activate human dendritic cells and peritoneal macro-
phages leading to type I IFN production.26,27
Importantly, we also showed that, irrespective of the
method of administration (prior to or simultaneously
with LPS stimulation), these small molecules inhibited
the production of LPS/TLR4-driven IFN proteins
(IFN-b and IP-10). Interestingly, we obtained similar
results regarding MyD88-dependent TLR4 signalling
in prior and simultaneous administration, where FP7
attenuated LPS stimulation in THP-1 macrophages
(inhibiting the production of IL-1b and TNF-a. 16
While this negative effect on the production of IFN-b
and IP-10 was also seen when FP7 was administered 30
min after LPS, FP12 reduced only IP-10 production,
however IFN-b release did not appear to be affected
post factum. This important pharmacological effect of
FP7 and FP12 could be explained by competition
between LPS and FP7/FP12 which bind to MD-2
and displace LPS.13 In this respect, we have already
demonstrated the ability of FP7 to prevent LPS-
driven TLR4 and CD14 internalisation, suggesting
that FP7 can interact with both TLR4/MD-2 and
CD14 and prevent activation of MyD88 and TRIF-
dependent signalling in PBMC.25 Furthermore, the
small differences in the potential of these small mole-
cules to affect MyD88-dependent and MyD88-
independent TLR4 signalling (administered 30 min
after LPS) might be affected by internalisation of
TLR4 in the cell cytoplasm. In this respect, it has
been demonstrated that Rab10 is required for
trafficking of TLR4 between the membrane and the
Golgi apparatus, and TICAM-1/TICAM-2/TLR4 are
essential for endosome localisation of TLR4-mediated
IFN signalling.28,29 Furthermore, CD14 is required for
LPS-induced TLR4 internalisation into endosomes and
activation of TRIF pathways in macrophages.30
Additionally, CD14 deficiency completely blocked
TBK1/IRF3 activation without affecting MyD88-
dependent pathways. However, TLR4 endocytosis
and TRIF pathways are activated by distinct ligands
in the absence of CD14.19 Since Gram-negative patho-
gens produce both S- and R-forms of LPS, cells in the
absence of membrane-bound or soluble CD14 will be
able to recognise bacteria through R-form LPS.
Evidence from the literature has demonstrated differ-
ential recognition of R- and S-forms of LPS by TLR4-
MD-2. Freudenberg and colleagues demonstrated that
R-form of LPS and free lipid A activated MyD88-
dependent TLR4 signalling in the absence of CD14
and LPS-binding protein, which can lead to weaker
activation of TRIF-dependent pathways.31 Huber and
colleagues demonstrated that the Re-form can activate
MyD88-dependent but not TRIF-dependent TLR4
pathways in THP-1 macrophages. Further studies to
investigate the effect of FP7 and FP12 on downstream
targets in TLR4 signalling, including TLR4 internal-
isation and degradation are needed.
In conclusion, the results from this study demon-
strated the mechanism by which LPS/TLR4/TRIF sig-
nalling amplifies inflammatory response via type I IFN
pathways in THP-1 macrophages. Furthermore, we
showed that the synthetic TLR4 antagonists FP7 and
FP12 were effective in blocking MyD88-independent
TLR4 signalling, suggesting the potential of these
small molecules for pharmacological intervention of
inflammatory related diseases. Future work will be
focused on pre-clinical validation of FP7 and FP12
for treatment of virus-related infectious disorders and
sterile inflammation-driven diseases such as atheroscle-
rosis and aneurysms.
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